| Literature DB >> 33191482 |
Nico Maximilian Jandl1,2, Tobias Schmidt1, Tim Rolvien1,2, Julian Stürznickel1, Konstantin Chrysostomou1, Emil von Vopelius1,2, Alexander E Volk3, Thorsten Schinke1, Christian Kubisch3, Michael Amling1, Florian Barvencik4.
Abstract
Hypophosphatasia (HPP) is a rare inborn error of metabolism due to a decreased activity of tissue nonspecific alkaline phosphatase (TNSALP). As the onset and severity of HPP are heterogenous, it can be challenging to determine the pathogenicity of detected rare ALPL variants in symptomatic patients. We aimed to characterize patients with rare ALPL variants to propose which patients can be diagnosed with adult HPP. We included 72 patients with (1) clinical symptoms of adult HPP or positive family history and (2) low TNSALP activity and/or high pyridoxal 5'-phosphate (PLP) levels, who underwent ALPL gene sequencing. The patients were analyzed and divided into three groups depending on ALPL variant pathogenicity according to the classification of the American College of Medical Genetics and Genomics (ACMG). Reported pathogenic (n = 34 patients), rare (n = 17) and common (n = 21) ALPL variants only were found. Muscular complaints were the most frequent symptoms (> 80%), followed by bone affection (> 50%). Tooth involvement was significantly more common in patients with pathogenic or rare ALPL variants. Seven rare variants could be classified as likely pathogenic (ACMG class 4) of which five have not yet been described. Inconclusive genetic findings and less specific symptoms make diagnosis difficult in cases where adult HPP is not obvious. As not every pathogenic or rare ALPL variant leads to a manifestation of HPP, only patients with bone complications and at least one additional complication concerning teeth, muscle, central nervous and mental system, repeated low TNSALP activity and high PLP levels should be diagnosed as adult HPP if rare ALPL gene variants of ACMG class 4 or higher support the diagnosis.Entities:
Keywords: ALP; Alkaline phosphatase; HPP; PLP; Pyridoxal 5′-phosphate; TNSALP
Mesh:
Substances:
Year: 2020 PMID: 33191482 PMCID: PMC7881968 DOI: 10.1007/s00223-020-00771-7
Source DB: PubMed Journal: Calcif Tissue Int ISSN: 0171-967X Impact factor: 4.333